OCC OCC Clinical Trials & Evidence-Based Practice 3

Question 1

Which regulatory body provides oversight and approval for oncology clinical trials and new drug applications in the United States?

Accepted Answer

Food and Drug Administration (FDA)

Answer

The FDA regulates clinical trials and approves new drugs and biologics for marketing in the United States through the Investigational New Drug (IND) and New Drug Application (NDA) processes.

Question 2

A nurse researcher is reviewing a meta-analysis on antiemetic efficacy. What does this study design involve?

Accepted Answer

Statistical pooling of results from multiple independent studies on the same question

Answer

A meta-analysis statistically combines results from multiple independent studies to increase statistical power and provide a more precise estimate of treatment effect.

Question 3

An oncology patient asks the nurse about expanded access (compassionate use) for an unapproved drug. What is the nurse's BEST response?

Accepted Answer

Expanded access may allow seriously ill patients to access investigational drugs outside of a clinical trial; the provider can apply through the FDA

Answer

The FDA's expanded access program allows seriously ill patients who lack alternatives to access investigational drugs outside of clinical trials, with the treating physician submitting a request to the FDA.

Question 4

Which outcome measure is MOST important to patients and is increasingly required in oncology clinical trial reporting?

Accepted Answer

Patient-reported outcomes (PROs) including quality of life

Answer

Patient-reported outcomes (PROs), including quality of life measures, capture the patient's perspective on treatment burden and benefit, increasingly required by the FDA in oncology trial reporting.

Question 5

A patient is being screened for a clinical trial and is found to have a liver function test that exceeds the protocol's eligibility criteria. What does the nurse understand about this?

Accepted Answer

The patient cannot be enrolled; eligibility criteria are legally binding safety parameters that cannot be waived

Answer

Clinical trial eligibility criteria are binding safety and scientific parameters established in the protocol; enrollment of ineligible patients constitutes a protocol deviation or violation.

(OCC) Oncology Chemotherapy Certification Practice Test

(OCC) Oncology Chemotherapy Certification Practice Test

OCC OCC Clinical Trials & Evidence-Based Practice 3